AXCELLA ANNOUNCES PATENT ISSUANCE FOR AXA CANDIDATE AXA1125 METHODS OF USE

  • Patent issuance from Axcella’s broad Endogenous Metabolic Modulator (EMM) portfolio

  • Claims cover methods of use of EMM compositions in liver dysfunction and liver disease

  • Issuance expands protection of Axcella’s pipeline of AXA Candidates

CAMBRIDGE, Mass., April 2, 2019 – Axcella Health, a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced the issuance of U.S. Patent 10,238,617 with claims covering methods of use for AXA Candidate AXA1125, the Company’s EMM composition, to address liver dysfunction and liver disease, including fatty liver disease. The patent was issued on March 26, 2019.

“This issuance covers use of a broader class of EMM compositions and expands Axcella’s protection of our AXA Candidates, and proprietary human-focused AXA Development Platform,” said Paul F. Fehlner, J.D., Ph.D., Senior Vice President, Chief Intellectual Property Officer of Axcella. “These patents and our entire portfolio are fully owned by Axcella.”

AXA1125 is a novel composition of EMMs designed to simultaneously support metabolic, inflammatory and fibrotic pathways associated with liver health. Axcella was previously granted a patent related to AXA1125 with claims covering compositions of matter independent of any particular use.

“This additional issuance continues to strengthen our global intellectual property position with patent rights that include coverage for our AXA Candidates, manufacturing and formulations,” said Bill Hinshaw, President and Chief Executive Officer of Axcella.

About Endogenous Metabolic Modulators

Endogenous metabolic modulators are a broad family of molecules, including amino acids, which fundamentally impact and regulate human metabolism. Our AXA Candidates are comprised of EMMs that individually have a history of safe use as food. We believe that, unlike conventional targeted interventions currently used to address dysregulated metabolism, EMM compositions have the potential to directly and simultaneously modulate multiple metabolic pathways implicated both in complex diseases and overall health.

About Non-IND, IRB-Approved Clinical Studies

Axcella conducts Institutional Review Board (IRB)-approved, non-investigational new drug application (Non-IND) clinical studies in humans with its AXA candidates under U.S. Food and Drug Administration regulations and guidance supporting research with food. In these studies, Axcella evaluates in humans, including in individuals with disease, AXA Candidates for safety, tolerability and effects on the normal structures and functions of the body. Non-IND, IRB-Approved Clinical Studies are not designed or intended to evaluate an AXA Candidate’s ability to diagnose, cure, mitigate, treat or prevent a disease. If Axcella decides to further develop an AXA Candidate as a potential therapeutic, subsequent studies will be conducted under an IND.

About Axcella Health

Axcella is designing and developing AXA candidates, compositions of EMMs matched to biologies and engineered in distinct ratios, with the aim of maximizing the vital role that EMMs play in regulating multiple metabolic functions. Our AXA Candidates are generated from our proprietary, human-focused AXA Development Platform and harness the power of EMMs, a broad family of molecules that fundamentally impact and regulate human metabolism. We believe our leading expertise and capabilities in EMMs position us to become a preeminent company reprogramming metabolism to address a diverse set of complex diseases and support health. Our AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and CNS. We were founded by Flagship Pioneering. www.axcellahealth.com

# # #

Media Contact
Stefanie Tuck
MacDougall Biomedical Communications
stuck@macbiocom.com
781-235-3060

Company Contact
Alison Williams
awilliams@axcellahealth.com
857-320-2200